Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT01231321
First received: October 28, 2010
Last updated: April 20, 2011
Last verified: April 2011

October 28, 2010
April 20, 2011
December 2007
February 2010   (final data collection date for primary outcome measure)
  • Frequency of Adverse Events [ Time Frame: Up to 34 weeks (24 week study treatment plus 70-day follow-up period) ] [ Designated as safety issue: Yes ]

    Serious adverse events were collected from the time of informed consent, and nonserious adverse events were collected from the time of first dose of adalimumab, until 70 days after the last injection of adalimumab. Refer to the Reported Adverse Events section of this results disclosure for specific adverse events reported.

    Note:

    Severe events considerably interfered in patients' usual activities and may have been life-threatening.

    Serious events were life-threatening; resulted in hospitalization, congenital anomalies, or disability; or required intervention to prevent seriousness.

  • Changes of Physical Examination [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: Yes ]
    Physical examination findings were compared between Baseline and Week 24, and changes were recorded (Normal at Baseline to Abnormal at Week 24; or Abnormal at Baseline to Normal at Week 24). Physical examination criteria (normal vs. abnormal) were at the clinical judgement of the examining physician. Significant changes in physical examination from Baseline were considered to be adverse events.
  • Deviation From Normal Laboratory Ranges [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

    Laboratory values were assessed for values above and below the normal (reference) ranges used by the central laboratory.

    Note abbreviations used in table:

    Alk. phosphatase = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ESR = erythrocyte sedimentation rate

  • Vital Sign Values [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

    Vital signs values were assessed for values above and below the normal (reference) ranges used by the central laboratory.

    Note, in table, BP = blood pressure.

  • Changes of physical examination [ Time Frame: For a duration of 24 weeks, beginning at Screening visit and ending after the completion of Study Week 24 ] [ Designated as safety issue: Yes ]
    Significant change in physical examination from Baseline will be considered as Adverse Event
  • Deviation from normal laboratory ranges [ Time Frame: For a duration of 24 weeks, beginning at Screening visit and ending after the completion of Study Week 24 ] [ Designated as safety issue: Yes ]
    Values will be checked for alert values, very high, very low values
  • Vital sign values [ Time Frame: For a duration of 24 weeks, beginning at Screening visit and ending after the completion of Study Week 24 ] [ Designated as safety issue: Yes ]
    Values will be checked for alert values, very high, very low values
  • Frequency of Adverse Events [ Time Frame: For the continuous duration of time beginning when Informed consent was signed to 70 days after the last injection of adalimumab ] [ Designated as safety issue: Yes ]
    Adverse Events will be collected from Informed consent was signed by Subject to 70 days after the last injection of adalimumab. All collected Adverse Events will be summarized by 1 Subject and system organ class and Adverse Events terminology.
Complete list of historical versions of study NCT01231321 on ClinicalTrials.gov Archive Site
Change in Disease Activity Score (DAS28) Compared With Baseline [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: No ]
The DAS28 is validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health (patient's global assessment of disease activity) were included in the DAS28 score. Scores on the DAS28 range from 1 (inactive disease) to 10 (very active disease).
Efficacy will be evaluated by change in disease activity score (DAS28) compared with study entry and at Week 24. [ Time Frame: For a duration up to 24 weeks, beginning at Baseline and ending after the completion of Study Week 24 ] [ Designated as safety issue: No ]
To demonstrate the efficacy of adalimumab when added to preexisting inadequate standard anti-rheumatic therapy in patients with moderate to severely active Rhumatoid Arthritis (RA).
Not Provided
Not Provided
 
A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available for participants not receiving concomitant disease-modifying antirheumatic drugs (DMARDs) who did not achieve American College of Rheumatology 20 (ACR20) criteria after 12 weeks of treatment. Efficacy and safety measurements were performed throughout the study.

This is an open-label, multicenter study designed to establish the safety and efficacy of adalimumab in the treatment of moderate to severely active rheumatoid arthritis. A total of 100 subjects with inadequate preexisting standard anti-rheumatic therapy were enrolled at 5 sites in Russia.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Rheumatoid Arthritis
Drug: adalimumab
Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
Other Names:
  • ABT-D2E7
  • adalimumab
  • Humira
Experimental: adalimumab
Adalimumab / pre-filled syringe 40 mg/0.8 ml
Intervention: Drug: adalimumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females >= 18 years of age.
  2. A negative pregnancy test (human chorionic gonadotropin in serum samples) for women of childbearing potential prior to start of study treatment.
  3. Female subject is either not of childbearing potential, defined as postmenopausal (at least 1 year since last menses) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control throughout the study and for 150 days after study completion:

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device.
    • Contraceptives (oral, parenteral, patch) for three months prior to study drug administration.
    • A vasectomized partner.
  4. American College of Rheumatology criteria for diagnosis of rheumatoid arthritis for at least 6 months.
  5. Subjects must meet the following three criteria:

    • Disease Activity Score (28 joints) more or equal 3.2 (at Baseline only)
    • At least 6 swollen joints out of the 66 assessed
    • At least 8 tender joints out of the 68 assessed
  6. Subjects must have a C-reactive protein >= 1.5mg/dL or erythrocyte sedimentation rate >= 28 mm/1h.
  7. Unsatisfactory response or intolerance to prior disease modifying anti-rheumatic drugs (must have failed at least 1 disease modifying anti-rheumatic drug).
  8. Able and willing to administer subcutaneous injections.
  9. Able and willing to give written informed consent and to comply with the requirements of the study protocol.
  10. Documented negative purified protein derivative test, defined as < 5 mm induration, or willingness and ability to start tuberculosis prophylaxis before first dose of study drug if the purified protein derivative result is positive and the chest X-ray is not suggestive of active tuberculosis and there is no history of active tuberculosis.

Exclusion Criteria:

  1. Prior treatment with alkylating agents such as cyclophosphamide or chlorambucil within at least 5 years before enrollment.
  2. Prior treatment with intravenous immunoglobulin or any investigational agent "chemical" in nature within 30 days, or 5 half lives of the product, whichever is longer.
  3. Prior treatment with cyclosporine within the last 6 months.
  4. Prior treatment with investigational biologic therapy.
  5. Subject has chronic arthritis diagnosis before the age 17 years.
  6. Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study).
  7. History of an allergic reaction or significant sensitivity to the constituents of study drug (adalimumab).
  8. Treatment within the last 2 months with approved biologic therapy (e.g. infliximab) prior to Baseline.
  9. Prior treatment with total lymphoid irradiation.
  10. History of cancer or lymphoproliferative disease other than a successfully and completely treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
  11. History of or current acute inflammatory joint disease of origin other than rheumatoid arthritis, e.g. mixed connective tissue disease, systemic lupus erythematosus etc.
  12. History of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (New York Heart Association III-IV), active peptic ulcer disease, recent stroke (within 3 months) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  13. Subject is known to have immune deficiency, history of positive human immunodeficiency virus status or is immunocompromised.
  14. Persistent chronic infection, or severe infections requiring hospitalization or treatment with intravenous antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.
  15. Female subjects who are pregnant or breast-feeding or is considering becoming pregnant during the study or for 150 days after the last dose of study medication.
  16. History of clinically significant drug or alcohol abuse in the last year.
  17. Previous diagnosis or signs of central nervous system demyelinating diseases.
  18. History of untreated or active tuberculosis, histoplasmosis or listeriosis.
  19. History of clinically significant hematologic (e.g. severe anemia, leucopenia, thrombocytopenia), renal or liver disease (e.g. fibrosis, cirrhosis, hepatitis).
  20. Screening clinical laboratory analysis showing any of the following abnormal laboratory results:

    • Aspartate transaminase or alanine transaminase > 1.75 x the upper limit of normal.
    • Serum total bilirubin >= 1.5 mg/dL (>= 26 micromol/L).
    • Creatinine > 1.5 mg/dL (133 micromol/L) in subjects < 65 years old and > upper limit of normal range in subjects >= 65 years old.
    • Positive Hepatitis B or C serology indicative of previous or current infections.
  21. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT01231321
W06-406
Yes
Konstantin Gudkov/ Clinical Research Manager, Abbott Laboratories LLC Russia
Abbott
Not Provided
Study Director: Konstantin Gudkov, MD Abbott
Abbott
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP